FDA Granted Breakthrough Status to APS Pregnancy Drug
The designation aims to speed up the development of a treatment for pregnant individuals with antiphospholipid syndrome.
Updated on Sept. 22, 2026 in Pregnancy
Live Poll
Should federal regulators prioritize faster development paths for new treatments for rare medical conditions?
The FDA has granted Breakthrough Therapy designation to CIMZIA, a tumor necrosis factor inhibitor, for preventing adverse pregnancy outcomes in women with antiphospholipid syndrome (APS). This marks a significant step for patients with the autoimmune disorder who currently lack FDA-approved options for these complications.
Why it matters
Currently, no FDA-approved therapies exist specifically to prevent adverse pregnancy outcomes in women with APS. This designation is intended to accelerate the development and review of CIMZIA to address this urgent clinical gap.
Preliminary evidence from the IMPACT study suggests the potential for substantial clinical improvement over existing treatments. While promising, the safety and efficacy of CIMZIA for this specific indication have not yet been established.
The players
FDA
The federal agency responsible for regulating pharmaceuticals and approving new medical treatments in the United States.
UCB
A biopharmaceutical company focused on developing therapies for severe immune and neurological conditions, including CIMZIA.
The details
CIMZIA is a tumor necrosis factor (TNF) inhibitor that functions by blocking TNF activity to reduce inflammation. Administered by injection, the medication is being studied for its potential to prevent placenta-mediated adverse pregnancy outcomes associated with APS. The drug is already being investigated for this use, following its earlier status as an Orphan Drug for the condition.
Timeline
September 22, 2026
Health Landscape
This development marks a potential shift in the management of autoimmune-related pregnancy complications, where options have remained limited. It follows a historical pattern of using the Breakthrough Therapy pathway to prioritize research in areas of high unmet medical need.
Patients with antiphospholipid syndrome should discuss this development with their obstetrician or rheumatologist to understand current treatment standards and the status of clinical research. Because CIMZIA's efficacy for this specific purpose is not yet established, no changes to existing treatment plans should be made.
The takeaway
The FDA has fast-tracked the review process for CIMZIA as a potential therapy for APS-related pregnancy complications. Patients should continue working closely with their specialized medical team to manage autoimmune health and monitor for upcoming clinical trial results.
Further reading
Learn more about managing health during Pregnancy.
Source note: This article includes information reported by Pharmafocusasia.
Live Poll
Should federal regulators prioritize faster development paths for new treatments for rare medical conditions?
